deferasirox has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amano, R; Asano, Y; Fujita, H; Goto, W; Hirakawa, K; Kashiwagi, S; Morisaki, T; Ohira, M; Shibutani, M; Takada, K; Takahashi, K; Takashima, T; Tomita, S | 1 |
| Assayag, F; Becette, V; Bièche, I; Bonin, F; Callens, C; Caly, M; Chateau-Joubert, S; de la Grange, P; Gentien, D; Lallemand, F; Marangoni, E; Rapinat, A; Schnitzler, A; Servely, JL; Tury, S; Vacher, S | 1 |
2 other study(ies) available for deferasirox and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment.
Topics: Animals; Antigens, CD; B7-H1 Antigen; Cadherins; Cell Cycle; Cell Line, Tumor; Deferasirox; Deferoxamine; Epithelial-Mesenchymal Transition; Female; Furans; Humans; Iron; Iron Chelating Agents; Iron Deficiencies; Ketones; Mice; Mice, Inbred BALB C; Mice, Nude; RNA, Messenger; RNA, Neoplasm; Triple Negative Breast Neoplasms; Tubulin Modulators; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2020 |
The iron chelator deferasirox synergises with chemotherapy to treat triple-negative breast cancers.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carboplatin; Cell Proliferation; Cisplatin; Deferasirox; Doxorubicin; Drug Synergism; Humans; Iron; Iron Chelating Agents; MCF-7 Cells; Mice, Nude; NF-kappa B; Phosphatidylinositol 3-Kinase; Signal Transduction; Time Factors; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2018 |